{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:46:54Z","timestamp":1740138414318,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12020-018-1806-y","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T05:46:19Z","timestamp":1541655979000},"page":"651-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term control of Paget\u2019s disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a \u201creal world\u201d setting"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-9615","authenticated-orcid":false,"given":"Yair","family":"Liel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-0927","authenticated-orcid":false,"given":"Muhammad","family":"Abu Tailakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"1806_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00774-006-0696-x","volume":"24","author":"S Takata","year":"2006","unstructured":"S. Takata, J. Hashimoto, K. Nakatsuka, N. Yoshimura, K. Yoh, I. Ohno et al. Guidelines for diagnosis and management of Paget\u2019s disease of bone in Japan. J. Bone Miner. Metab. 24, 359\u2013367 (2006)","journal-title":"J. Bone Miner. Metab."},{"key":"1806_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00198-008-0629-8","volume":"19","author":"JP Devogelaer","year":"2008","unstructured":"J.P. Devogelaer, P. Bergmann, J.J. Body, Y. Boutsen, S. Goemaere, J.M. Kaufman et al. Management of patients with Paget\u2019s disease: a consensus document of the Belgian Bone Club. Osteoporos. Int. 19, 1109\u20131117 (2008)","journal-title":"Osteoporos. Int."},{"key":"1806_CR3","doi-asserted-by":"crossref","unstructured":"E.S Siris, G.D Roodman. Paget\u2019s disease of bone. In Primer on the metabolic bone diseases and disorders of mineral metabolism, ed by Rosen C.J, Bouillon R., Compston J.E., Rosen V. 8 edn. (Wiley-Blackwell, Danvers, MA, 2013) pp. 659-668.","DOI":"10.1002\/9781118453926.ch80"},{"key":"1806_CR4","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1210\/jc.2014-2910","volume":"99","author":"FR Singer","year":"2014","unstructured":"F.R. Singer, H.G. Bone, D.J. Hosking, K.W. Lyles, M.H. Murad, I.R. Reid et al. Paget\u2019s disease of bone: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 4408\u20134422 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1806_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10354-016-0502-x","volume":"167","author":"C Muschitz","year":"2017","unstructured":"C. Muschitz, X. Feichtinger, J. Haschka, R. Kocijan, Diagnosis and treatment of Paget\u2019s disease of bone: a clinical practice guideline. Wien. Med. Wochenschr. 167, 18\u201324 (2017)","journal-title":"Wien. Med. Wochenschr."},{"key":"1806_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1507\/endocrj.50.385","volume":"50","author":"M Hoshiro","year":"2003","unstructured":"M. Hoshiro, T. Harada, H. Iwai, T. Miyatake, A. Nishimura, Y. Ohno et al. Two cases of monostotic Paget\u2019s disease: effects of bisphosphonate. Endocr. J. 50, 385\u2013392 (2003)","journal-title":"Endocr. J."},{"key":"1806_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00774-005-0609-4","volume":"23","author":"J Takada","year":"2005","unstructured":"J. Takada, K. Iba, T. Yamashita, Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget\u2019s disease of bone. J. Bone Miner. Metab. 23, 333\u2013336 (2005)","journal-title":"J. Bone Miner. Metab."},{"key":"1806_CR8","first-page":"525","volume":"54","author":"Anjali","year":"2006","unstructured":"Anjali, N. Thomas, S. Rajaratnam, N. Shanthly, R. Oommen, M.S. Seshadri, Paget\u2019s disease of bone: experience from a centre in southern India. J. Assoc. Physicians India 54, 525\u2013529 (2006)","journal-title":"J. Assoc. Physicians India"},{"key":"1806_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bone.2008.01.024","volume":"42","author":"JP Walsh","year":"2008","unstructured":"J.P. Walsh, R. Attewell, B.G. Stuckey, M.J. Hooper, J.D. Wark, S. Fletcher et al. Treatment of Paget\u2019s disease of bone: a survey of clinical practice in Australia. Bone 42, 1219\u20131225 (2008)","journal-title":"Bone"},{"key":"1806_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/0002-9343(85)90055-5","volume":"79","author":"RD Altman","year":"1985","unstructured":"R.D. Altman, Long-term follow-up of therapy with intermittent etidronate disodium in Paget\u2019s disease of bone. Am. J. Med. 79, 583\u2013590 (1985)","journal-title":"Am. J. Med."},{"key":"1806_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/8756-3282(94)90818-4","volume":"15","author":"S Adami","year":"1994","unstructured":"S. Adami, M. Mian, P. Gatti, M. Rossini, N. Zamberlan, F. Bertoldo et al. Effects of two oral doses of alendronate in the treatment of Paget\u2019s disease of bone. Bone 15, 415\u2013417 (1994)","journal-title":"Bone"},{"key":"1806_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S8756-3282(96)00364-X","volume":"20","author":"SA Khan","year":"1997","unstructured":"S.A. Khan, S. Vasikaran, E.V. McCloskey, M.N. Beneton, S. Rogers, L. Coulton et al. Alendronate in the treatment of Paget\u2019s disease of bone. Bone 20, 263\u2013271 (1997)","journal-title":"Bone"},{"key":"1806_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s002239900584","volume":"64","author":"JP Brown","year":"1999","unstructured":"J.P. Brown, D.J. Hosking, L. Ste-Marie, C.C.J. Johnston, J. Reginster, W.G. Ryan et al. Risedronate, a highly effective, short-term oral treatment for Paget\u2019s disease: a dose-response study. Calcif. Tissue Int. 64, 93\u201399 (1999)","journal-title":"Calcif. Tissue Int."},{"key":"1806_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-4-166","volume":"4","author":"K Iba","year":"2010","unstructured":"K. Iba, J. Takada, T. Wada, T. Yamashita, Five-year follow-up of Japanese patients with Paget\u2019s disease of the bone after treatment with low-dose oral alendronate: a case series. J. Med. Case Rep. 4, 166 (2010)","journal-title":"J. Med. Case Rep."},{"key":"1806_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1353\/pbm.2002.0070","volume":"45","author":"JR Hampton","year":"2002","unstructured":"J.R. Hampton, Evidence-based medicine, opinion-based medicine, and real-world medicine. Perspect. Biol. Med. 45, 549\u2013568 (2002)","journal-title":"Perspect. Biol. Med."},{"key":"1806_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bone.2010.09.002","volume":"49","author":"IR Reid","year":"2011","unstructured":"I.R. Reid, D.J. Hosking, Bisphosphonates in Paget\u2019s disease. Bone 49, 89\u201394 (2011)","journal-title":"Bone"},{"key":"1806_CR17","first-page":"755","volume":"64","author":"RE Gray","year":"1987","unstructured":"R.E. Gray, A.J. Yates, C.J. Preston, R. Smith, R.G. Russell, J.A. Kanis, Duration of effect of oral diphosphonate therapy in Paget\u2019s disease of bone. Q. J. Med. 64, 755\u2013767 (1987)","journal-title":"Q. J. Med."},{"key":"1806_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/8756-3282(95)00437-8","volume":"18","author":"SA Khan","year":"1996","unstructured":"S.A. Khan, E.V. McCloskey, K. Nakatsuka, J. Orgee, G.M. Coombes, J.A. Kanis, Duration of response with oral clodronate in Paget\u2019s disease of bone. Bone 18, 185\u2013190 (1996)","journal-title":"Bone"},{"key":"1806_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4158\/EP171781.OR","volume":"23","author":"Y Liel","year":"2017","unstructured":"Y. Liel, Y. Plakht, M. Abu Tailakh, Bone turnover in osteoporotic women during long-term oral bisphosphonates treatment. Implications for treatment failure and \"drug holiday\" in the real world. Endocr. Pract 23, 787\u2013793 (2017).","journal-title":"Endocr. Pract"},{"key":"1806_CR20","doi-asserted-by":"publisher","first-page":"L45","DOI":"10.1210\/jc.2015-1631","volume":"100","author":"SH Ralston","year":"2015","unstructured":"S.H. Ralston, L. Corral-Gudino, W.D. Fraser, L. Gennari, N. Gua\u00f1abens, P.L. Selby, Letter to the Editor: the endocrine society clinical practice guidelines on Paget\u2019s disease: many recommendations are not evidence based. J. Clin. Endocrinol. Metab. 100, L45\u2013L46 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1806_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1359\/jbmr.090709","volume":"25","author":"AL Langston","year":"2010","unstructured":"A.L. Langston, M.K. Campbell, W.D. Fraser, G.S. MacLennan, P.L. Selby, S.H. Ralston et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget\u2019s disease of bone. J. Bone Miner. Res. 25, 20\u201331 (2010)","journal-title":"J. Bone Miner. Res."},{"key":"1806_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/jbmr.3066","volume":"32","author":"A Tan","year":"2017","unstructured":"A. Tan, K. Goodman, A. Walker, J. Hudson, G.S. MacLennan, P.L. Selby et al. Long-term randomized trial of intensive versus symptomatic management in Paget\u2019s disease of bone: The PRISM-EZ Study. J. Bone Miner. Res. 32, 1165\u20131173 (2017)","journal-title":"J. Bone Miner. Res."},{"key":"1806_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00198-015-3095-0","volume":"26","author":"AA Al Nofal","year":"2015","unstructured":"A.A. Al Nofal, O. Altayar, K. BenKhadra, O.Q. Qasim Agha, N. Asi, M. Nabhan et al. Bone turnover markers in Paget\u2019s disease of the bone: A Systematic review and meta-analysis. Osteoporos. Int. 26, 1875\u20131891 (2015)","journal-title":"Osteoporos. Int."},{"key":"1806_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"F.H. Ebetino, A.M. Hogan, S. Sun, M.K. Tsoumpra, X. Duan, J.T. Triffitt et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49, 20\u201333 (2011)","journal-title":"Bone"},{"key":"1806_CR25","first-page":"706","volume":"49","author":"P Peris","year":"2011","unstructured":"P. Peris, M. Torra, V. Olivares, R. Reyes, A. Monegal, A. Mart\u00ednez-Ferrer et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relatsh. Bone Turnover Bone 49, 706\u2013709 (2011)","journal-title":"Relatsh. Bone Turnover Bone"},{"key":"1806_CR26","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1210\/jc.2011-0412","volume":"96","author":"R Eastell","year":"2011","unstructured":"R. Eastell, R.A. Hannon, D. Wenderoth, J. Rodriguez-Moreno, A. Sawicki, Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 96, 3367\u20133373 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1806_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/jbmr.3156","volume":"32","author":"T Cundy","year":"2017","unstructured":"T. Cundy, Treating Paget\u2019s disease-why and how much? J. Bone Miner. Res. 32, 1163\u20131164 (2017)","journal-title":"J. Bone Miner. Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1806-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1806-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T19:27:05Z","timestamp":1573154825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1806-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1806"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1806-y","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Soroka Medical Center Human Research Review Board in accordance with the Declaration of Helsinki. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}